
Illinois, USA-based Long Grove Pharmaceuticals, founded in 2019 by strategic health care investor Water Street Healthcare Partners, will begin shipping its first products in mid-2022. Dedicated to bringing high-demand, high-quality health care products to niche markets, the company says it is uniquely positioned to become a new leader in the generic pharmaceutical market.
Long Grove Pharmaceuticals specializes in generic development opportunities with complex formulations, challenging manufacturing and supply chain dynamics, and unique regulatory approval pathways. The company is spearheaded by a multi-functional team of leaders with more than 100 years of collective pharmaceutical experience. Together, they are pursuing partnership and product development initiatives focused on bringing long-awaited products to market across the hospital pharmacy, retail, clinic, and alternative site channels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze